Table 2.

Univariate and multivariate analysis for PFS in patients with anti-PD-1 therapy with 1,000 bootstraping.

	Univariate analysis			Multivariate analysis
	HR	95% CI	P-value	HR	95% CI	P-value	Bootstrapping 95% CI
PFS
Age
≤ median	1
>median	1.167	0.577–2.357	0.668
Gender
Female	1
Male	0.940	0.646–1.367	0.745
Exosomal PD-L1
Low	1			1
High	3.017	1.439–6.325	0.003	2.746	1.287–5.861	0.009	1.627–8.480
Exosomal PD-1
Low	1
High	1.582	0.709–3.532	0.263
CD28
Low	1			1
High	0.394	0.192–0.811	0.011	0.430	0.206–0.897	0.025	0.151–0.865
CD80
Low	1
High	0.516	0.253–1.054	0.069			0.723
CD86
Low	1
High	0.409	0.182–0.915	0.030			0.789
GITRL
Low	1
High	0.409	0.182–0.915	0.030			0.789
ICOS
Low	1
High	0.494	0.233–1.045	0.065			0.781
TLR-2
Low	1
High	0.348	0.149–0.812	0.015			0.386
BTLA
Low	1
High	0.520	0.258–1.047	0.067			0.154
LAG-3
Low	1
High	0.611	0.309–1.211	0.158
CTLA-4
Low	1
High	0.511	0.256–1.022	0.058			0.972
Pathological type
Other	1
Adenocarcinoma	1.106	0.568–2.153	0.768
Number of previous treatment lines
0,1	1
≥2	1.832	0.747–4.496	0.186
Response of previous treatment lines
Non-response	1
Response	0.865	0.392–1.910	0.720
Type of metastatic sites
Viscera organ	1
Others	0.841	0.414–1.708	0.841
Number of metastatic sites
1	1
≥2	1.143	0.573–2.281	0.705